모야모야병 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the moyamoya disease market size is projected to expand from USD 1.31 billion in 2025 and USD 1.38 billion in 2026 to USD 1.8 billion by 2031, registering a CAGR of 5.45% between 2026 to 2031.

This report is Segmented by Offering (Diagnosis [Magnetic Resonance Angiography and More], Treatment [Surgical Revascularization and More]), Patient Demographic (Pediatric, Adult, and More), Clinical Presentation (Ischemic, Hemorrhagic, and More), End User (Hospitals, Ambulatory Surgical Centers, and More), and Geography (North America, Europe, and More). Forecasts are in Terms of Value (USD).

Global Moyamoya Disease Market Trends and Insights

Rising Diagnosis Through Advanced Neurovascular Imaging

Imaging quality determines how quickly clinicians can move from suspected symptoms to a confirmed diagnosis in the Moyamoya disease market. GE HealthCare received FDA 510(k) clearance in February 2026 for SIGNA Sprint with Freelium, SIGNA Bolt, and the SIGNA One workflow platform, which can support MRA and perfusion imaging protocols used for moyamoya disease. Philips introduced the BlueSeal Horizon helium-free 3.0T MRI platform in November 2025 with clinical AI capabilities for neuroimaging workflows. These systems can improve vessel visualization, shorten scans, and reduce infrastructure constraints for hospitals that need advanced imaging. Japan's guidelines allow 1.5T or higher MRA to support bilateral definitive diagnosis, reducing reliance on invasive DSA referrals and increasing MRI use across a broader hospital base. Earlier identification can increase the number of patients assessed for surgery and long-term surveillance. This supports diagnostic activity across the Moyamoya disease market without changing the central role of specialist interpretation. The Moyamoya disease market benefits when high-quality imaging becomes available beyond major referral centers.

Higher Recognition of Pediatric and Adult Stroke Phenotypes

Pediatric moyamoya disease commonly presents with ischemic events, including transient ischemic attacks, infarcts, and cognitive decline, while adult onset is more often hemorrhagic, particularly after age 40. Recognition of this age-related pattern had been limited, which delayed referrals in both populations. China's 2025 expert consensus and Japan's 2025 guidelines formalized symptom-based screening pathways that can support earlier evaluation. A 2026 review found that asymptomatic disease still carried a risk of ischemic or hemorrhagic stroke and radiological progression during 2 years of follow-up. Broader surveillance can expand demand for imaging and preventive revascularization in the Moyamoya disease market. It also makes existing diagnosed-case counts less representative of the full population requiring monitoring.

Limited High-Level Evidence and Heterogeneous Treatment Guidelines

Moyamoya disease lacks the randomized controlled trial base that payers often use for standard reimbursement decisions. A multicenter North American retrospective study found symptomatic stroke rates of 11.6% after direct revascularization and 9.6% after indirect revascularization, without a statistically significant difference. The European Stroke Organisation noted that the quality of evidence for surgical decisions is limited compared with other cerebrovascular conditions. In the United States, there is no national or local coverage determination for revascularization, which leaves insurers to apply their own review criteria. This inconsistency can delay treatment and make referral patterns less predictable. It also limits access to adjunctive drugs and weakens incentives for large medical-management trials in the Moyamoya disease market.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Specialist Revascularization Capacity
2. AI-Assisted MRA and Retinal Screening for Case Finding
3. High Surgical Complexity and Concentration of Expertise

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Treatment held 68.31% of the Moyamoya disease market share in 2025, supported by surgical revascularization as the established approach for symptomatic disease. Direct STA-MCA bypass has high procedural revenue intensity because it requires complex surgical care and supporting imaging. A 2026 cohort study found that modified extracranial-intracranial combined bypass produced stronger functional independence and hemodynamic restoration than indirect bypass in adults with ischemic disease. Medical management includes antiplatelet treatment, such as aspirin and cilostazol, and serves lower-acuity and postoperative populations at lower per-patient revenue. Rehabilitation and supportive care remain relevant for patients who require care for residual neurological or cognitive effects after treatment.

Diagnosis is projected to grow at a 6.38% CAGR from 2026 to 2031, making it the fastest-growing offering. DSA remains the reference test for complex or unilateral cases, while MRA and CT angiography are gaining use as image interpretation improves. SPECT, PET, ASL-MRI, and transcranial Doppler ultrasound support preoperative hemodynamic evaluation and postoperative surveillance. This layered workflow can create repeat imaging demand over extended follow-up periods. Radiation concerns for CTA and DSA, especially in children, are encouraging greater use of MRI-based options. This supports the diagnostic side of the Moyamoya disease industry while preserving DSA for cases that require detailed vascular assessment. The Moyamoya disease market can therefore gain from both advanced and lower-field MRI pathways.

Adult patients accounted for 55.44% of revenue in 2025. Their position reflects the higher hospitalization intensity of adult disease, including hemorrhagic presentations that are more common after age 40. The adult age distribution peaks between 35 and 39 years in East Asia and in the sixth decade in Western populations. This pattern supports continued adult revenue concentration in the Moyamoya disease market. Pregnant and postpartum patients also require individualized antiplatelet and revascularization planning because of their elevated ischemic risk during gestation. These patients create focused demand at tertiary obstetric-neurology centers.

Pediatric patients are forecast to grow at a 7.52% CAGR from 2026 to 2031. Japan's 2025 guidelines formalized symptom-based screening for childhood stroke, supporting earlier assessment at first presentation. A 2024 randomized trial reported benefit from remote ischemic conditioning before revascularization in pediatric disease. Earlier intervention extends the duration of imaging and follow-up monitoring for each patient. The others category includes secondary disease associated with sickle cell disease, Down syndrome, and neurofibromatosis type 1. Genetic screening programs that include RNF213 testing can identify some of these populations earlier.

Complete Report Scope:

• By Offering
  • Diagnosis
    • Digital Subtraction Angiography / Cerebral Angiography
    • Magnetic Resonance Angiography
    • Computed Tomography Angiography
    • Magnetic Resonance Imaging
    • Transcranial Doppler Ultrasound
    • SPECT and PET
    • Others
  • Treatment
    • Surgical Revascularization
    • Medical Management
    • Rehabilitation and Supportive Care
• By Patient Demographic
  • Pediatric Patients
  • Adult Patients
  • Pregnant and Postpartum Patients
  • Others
• By Clinical Presentation
  • Ischemic Presentation
  • Hemorrhagic Presentation
  • Transient Ischemic Attacks and Seizures
  • Cognitive and Neurodevelopmental Impairment
• By End User
  • Hospitals
  • Specialized Neurology and Neurosurgery Centers
  • Ambulatory Surgical Centers
  • Diagnostic Imaging Centers
  • Rehabilitation Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.61% of revenue in 2025. The region's position is supported by high per-procedure spending, with average hospitalization costs of USD 133,754 per case reported in the United States. The FY2026 ICD-10-CM designation I67.5 provides a billable code for moyamoya disease, which supports more consistent diagnostic coding. Canada's universal coverage supports revascularization for qualifying patients through provincial programs. Mexico has more limited public infrastructure, creating a two-tier regional pattern. Vanderbilt's prospective biomarker study also reflects North America's role in generating data that can influence care protocols. The Moyamoya disease market in the region benefits from this concentration of clinical and reimbursement infrastructure.

Asia-Pacific is forecast to grow at a 7.65% CAGR from 2026 to 2031 and has the highest disease burden. Japan reported prevalence of 10.5 per 100,000 and South Korea reported 16.1 per 100,000, while China reported 3.92 per 100,000 across a much larger population. Japan's 2025 guidelines allow MRA-based diagnosis without mandatory DSA in bilateral cases. China's 2025 expert consensus similarly supports standardized care across its expanding tertiary hospital network. India, South Korea, and Australia can benefit as neurosurgical training and advanced imaging capacity increase. A Korean study found a 1.08% RNF213 p.Arg4810Lys allele frequency in healthy participants, indicating a pool of people who may be identified through systematic screening.

Europe, the Middle East and Africa, and South America remain the emerging edge of the Moyamoya disease market. The European Stroke Organisation found that disease is likely underdiagnosed outside East Asia, with Western European incidence of 0.047 to 0.086 per 100,000. Germany, France, and the United Kingdom are the main European specialist hubs, while Italy and Spain are developing referral networks. Saudi Arabia and the United Arab Emirates are expanding advanced neurosurgical capacity, and South Africa remains the regional hub for complex cerebrovascular surgery. Limited specialist density continues to constrain scale across much of sub-Saharan Africa and South America. Wipro GE HealthCare launched the SIGNA Prime Elite, an AI-powered MRI system made in India, in January 2026 to expand imaging access in price-sensitive settings.

1. B. Braun
2. Bayer
3. Canon
4. Carl Zeiss
5. Chugai Pharmaceutical
6. Fujifilm Healthcare Corporation
7. GE HealthCare Technologies Inc.
8. Integra LifeSciences
9. iRegene Therapeutics Co., Ltd.
10. Johnson & Johnson
11. KLS Martin Group
12. Koninklijke Philips
13. Danaher
14. Medtronic
15. MicroVention
16. NeuroVasc Technologies
17. Novartis
18. Penumbra
19. Siemens Healthineers
20. Stryker
21. Takeda Pharmaceuticals
22. Terumo

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions and Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Diagnosis Through Advanced Neurovascular Imaging
  • 4.2.2 Higher Recognition of Pediatric and Adult Stroke Phenotypes
  • 4.2.3 Expansion of Specialist Revascularization Capacity
  • 4.2.4 Increasing Rare-Disease Research and Reimbursement Support
  • 4.2.5 AI-Assisted MRA and Retinal Screening for Case Finding
  • 4.2.6 Collateral-Promotion Therapies Creating an Adjunctive Treatment Category
• 4.3 Market Restraints
  • 4.3.1 Limited High-Level Evidence and Heterogeneous Treatment Guidelines
  • 4.3.2 High Surgical Complexity and Concentration of Expertise
  • 4.3.3 Perioperative Ischemia, Hyperperfusion and Hemorrhagic Risk
  • 4.3.4 Delayed Collateral Formation and Uncertain Commercial Path for Disease-Modifying Therapies
• 4.4 Value Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Offering
  • 5.1.1 Diagnosis
    • 5.1.1.1 Digital Subtraction Angiography / Cerebral Angiography
    • 5.1.1.2 Magnetic Resonance Angiography
    • 5.1.1.3 Computed Tomography Angiography
    • 5.1.1.4 Magnetic Resonance Imaging
    • 5.1.1.5 Transcranial Doppler Ultrasound
    • 5.1.1.6 SPECT and PET
    • 5.1.1.7 Others
  • 5.1.2 Treatment
    • 5.1.2.1 Surgical Revascularization
    • 5.1.2.2 Medical Management
    • 5.1.2.3 Rehabilitation and Supportive Care
• 5.2 By Patient Demographic
  • 5.2.1 Pediatric Patients
  • 5.2.2 Adult Patients
  • 5.2.3 Pregnant and Postpartum Patients
  • 5.2.4 Others
• 5.3 By Clinical Presentation
  • 5.3.1 Ischemic Presentation
  • 5.3.2 Hemorrhagic Presentation
  • 5.3.3 Transient Ischemic Attacks and Seizures
  • 5.3.4 Cognitive and Neurodevelopmental Impairment
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Specialized Neurology and Neurosurgery Centers
  • 5.4.3 Ambulatory Surgical Centers
  • 5.4.4 Diagnostic Imaging Centers
  • 5.4.5 Rehabilitation Centers
• 5.5 By Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 B. Braun SE
  • 6.3.2 Bayer AG
  • 6.3.3 Canon Medical Systems Corporation
  • 6.3.4 Carl Zeiss Meditec AG
  • 6.3.5 Chugai Pharmaceutical Co., Ltd.
  • 6.3.6 Fujifilm Healthcare Corporation
  • 6.3.7 GE HealthCare Technologies Inc.
  • 6.3.8 Integra LifeSciences Holdings Corporation
  • 6.3.9 iRegene Therapeutics Co., Ltd.
  • 6.3.10 Johnson & Johnson
  • 6.3.11 KLS Martin Group
  • 6.3.12 Koninklijke Philips N.V.
  • 6.3.13 Leica Microsystems GmbH
  • 6.3.14 Medtronic plc
  • 6.3.15 MicroVention, Inc.
  • 6.3.16 NeuroVasc Technologies, Inc.
  • 6.3.17 Novartis AG
  • 6.3.18 Penumbra, Inc.
  • 6.3.19 Siemens Healthineers AG
  • 6.3.20 Stryker Corporation
  • 6.3.21 Takeda Pharmaceutical Company Limited
  • 6.3.22 Terumo Corporation

7 Market Opportunities and Future Outlook

• 7.1 White-Space and Unmet-Need Assessment